Answers are grounded in this paper and cite their sources.
Introduction: Expanding incretin pharmacotherapy has prompted debate about declining bariatric surgery use. We examined procedure volumes during changes to Poland's coordinated bariatric care pilot (KOS-BAR) and growth in incretin drug sales. Methods: We analyzed National Health Fund procedure counts for 2022–2025 in 30 centers selected in a health technology assessment report. Nineteen centers had participated in the pilot and 11 had not. The principal comparison was total panel volume in 2023 versus 2024. Four exploratory exact rank-sum and sign tests assessed center changes, with Holm adjustment. Regulations and separate drug-sales aggregates provided context. Results: Panel volume increased from 5 515 procedures in 2022 to 7 667 in 2023, decreased to 6 735 in 2024 (− 12.2%), and increased to 7 455 in 2025 (+ 10.7%). The 2024 decline comprised 1 023 fewer procedures in pilot centers and 91 additional procedures elsewhere. Median center-level changes were − 25.3% and + 1.2%, respectively (Holm-adjusted p = 0.0112). Regulations implied a 177-day interval outside the pilot's operative timetable in 2024, without establishing center-specific suspension. Combined nominal sales value of semaglutide and tirzepatide increased from PLN 1.376 billion in 2024 to approximately PLN 3.056 billion in 2025. Procedure volume remained 2.8% below its 2023 peak. Conclusion: Expanding incretin sales were not accompanied by a sustained decline in panel volume. The decline in pilot centers was followed by recovery, highlighting care organization as context. Selected centers, annual aggregation, and sales measures preclude national extrapolation or identification of policy and drug effects.
No takes yet. Share an insight, caveat, or question.
Janik et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: